EyePoint Pharmaceuticals, Inc.
EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.25
Price-4.74%
-$0.61
1Y
Price
Market Cap
$1.027b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-6123.8%
EBITDA Margin-6183.4%
Net Profit Margin-6226.9%
Free Cash Flow Margin-6123.8%
EBITDA Margin-6183.4%
Net Profit Margin-6226.9%
Free Cash Flow MarginRevenue
$7.615m
-2.2%
1y CAGR+1.0%
3y CAGR+3.8%
5y CAGREarnings
-$271.599m
-57.2%
1y CAGR-37.1%
3y CAGR-46.6%
5y CAGREPS
-$3.50
-28.9%
1y CAGR-7.6%
3y CAGR-14.4%
5y CAGRBook Value
$230.472m
$288.217m
Assets$57.745m
Liabilities$22.314m
DebtDebt to Assets
7.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$271.540m
-64.0%
1y CAGR-2656.1%
3y CAGR-2000.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company